BioCentury
ARTICLE | Clinical News

Auris' Keyzilen misses in second Phase III tinnitus trial

March 30, 2018 3:18 PM UTC

Auris Medical Holding AG (NASDAQ:EARS) reported top-line data from the Phase III TACTT3 trial in about 893 patients with acute or post-acute peripheral tinnitus following traumatic cochlear injury or otitis media showing that repeated intratympanic injections of Keyzilen esketamine (AM-101) missed the primary endpoint of improving Tinnitus Functional Index (TFI) total score from baseline to day 84 vs. placebo. Secondary endpoints in the trial include patient-reported tinnitus loudness, patient-reported tinnitus annoyance, TFI sleep score, deterioration in hearing threshold and safety.

In 2016, Auris reported that Keyzilen missed the co-primary endpoints in the Phase III TACTT2 trial to treat acute peripheral tinnitus (see BioCentury, Aug. 22, 2016)...

BCIQ Company Profiles

Helomics Corp.

BCIQ Target Profiles

NMDA receptor